ALNY Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

319.855

Open

318.010

VWAP

318.21

Vol

193.11K

Mkt Cap

41.79B

Low

315.415

Amount

61.45M

EV/EBITDA(TTM)

51.38

Total Shares

133.51M

41.46B

EV/OCF(TTM)

58.15

P/S(TTM)

9.90

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Events Timeline

(ET)

2026-06-25

09:30:00

Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals

2026-06-03 (ET)

2026-06-03

16:50:00

Alnylam and Inceptive Sign Up to $2B Strategic Collaboration Agreement

2026-05-12 (ET)

2026-05-12

05:50:00

Alnylam Releases New Analyses Supporting Vutrisiran for Cardiac Amyloidosis Treatment

2026-05-07 (ET)

2026-05-07

09:40:00

MBX Biosciences Appoints Mark Soued as Chief Commercial Officer

News

9.5

07-02Fool

Alnylam Pharmaceuticals Shares Drop 24%, Yet Optimism Persists

9.5

07-02NASDAQ.COM

Alnylam Pharmaceuticals Reports Strong Q1 Performance

7.5

06-25Newsfilter

Komodo Expands Partnership with Alnylam to Enhance AI Decision-Making

9.0

06-23seekingalpha

Regeneron's Cemdisiran Marketing Applications Accepted by U.S. and European Regulators

5.0

06-23NASDAQ.COM

Dyne Therapeutics Appoints Barry Greene to Board of Directors

8.5

06-12Newsfilter

Alnylam to Host 10th RNAi Roundtable Series

17 Analyst Rating

Wall Street analysts forecast ALNY stock price to rise

14 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

351.00

Averages

479.53

High

580.00

Current: 0.000

Low

351.00

Averages

479.53

High

580.00

H.C. Wainwright

Buy

downgrade

$510 -> $470

AI Analysis

2026-06-29

Reason

H.C. Wainwright

Price Target

$510 -> $470

AI Analysis

2026-06-29

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Alnylam to $470 from $510 and keeps a Buy rating on the shares. The firm reduced its near-term estimates for Amvuttra but continues to estimate Alnylam's TTR franchise growing to over $20B in annual revenues by 2040.

Citi

NULL

Buy

initiated

$380

2026-05-18

Reason

Citi

Price Target

$380

2026-05-18

initiated

NULL

Buy

Reason

Citi initiated coverage of Alnylam with a Buy rating and $380 price target. The expanded launch of Amvuttra for ATTR-CM has \"no doubt been impressive,\" says the analyst, who views 28% year-to-date pullback as \"an attractive long-term entry point.\" Pressure has been led by competitor concerns, but the firm sees \"more tailwinds than headwinds for Amvuttra,\" the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALNY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY.O) is 34.13, compared to its 5-year average forward P/E of -36.90. For a more detailed relative valuation and DCF analysis to assess Alnylam Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-36.90

Current PE

34.13

Overvalued PE

38.64

Undervalued PE

-112.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7401.29

Current EV/EBITDA

23.84

Overvalued EV/EBITDA

51041.60

Undervalued EV/EBITDA

-65844.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

13.89

Current PS

5.73

Overvalued PS

18.37

Undervalued PS

9.41

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

xene swing trade

Intellectia · 61 candidates

Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, PharmaceuticalsRsi Category: moderateRelative Vol: >= 1.20List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA60Is Optionable: TrueSupport Resistance Relationship: PriceBreakResistance, PriceAroundResistance

Ticker

Name

Market Cap$

AVBP

ArriVent BioPharma Inc

1.41B

SCLX

Scilex Holding Co

75.57M

MGTX

MeiraGTx Holdings PLC

986.29M

TEVA

Teva Pharmaceutical Industries Limited..

41.13B

GILD

Gilead Sciences, Inc

166.90B

RVMD

Revolution Medicines Inc

33.48B

resistant to inflation stocks

Intellectia · 41 candidates

Sector: Consumer Cyclicals, Consumer Non-Cyclicals, Healthcare, Healthcare Services & Equipment, Industrials, Industrial & Commercial Services, Industrial Goods, UtilitiesIndustry: Electronic Equipment & Parts, Electric Utilities & IPPs, Food & Drug Retailing, Food & Tobacco, Healthcare Equipment & Supplies, Healthcare Providers & Services, Multiline Utilities, Pharmaceuticals, Professional & Commercial Services, Professional & Business Education, Water & Related UtilitiesRegion: USGross Margin: >= 40.00Beta: LowRiskCurrent Ratio: >= 1.50Operating Margin: >= 10.00Free Cash Flow Ttm: >= 0

Ticker

Name

Market Cap$

HALO

Halozyme Therapeutics Inc

8.14B

ZVRA

Zevra Therapeutics Inc

647.31M

ALNY

Alnylam Pharmaceuticals Inc

39.47B

INVA

Innoviva Inc

1.63B

GILD

Gilead Sciences, Inc

165.99B

CTAS

Cintas Corp

67.97B

What stocks have a new buy signal today?

Intellectia · 55 candidates

Market Cap: >= 5.00BRegion: USMarket Cap Category: large, mega, midPrice Change Pct: >= $4.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

ARM

Arm Holdings PLC

143.33B

SMMT

Summit Therapeutics Inc

12.05B

CHWY

Chewy Inc

9.73B

Planet Labs PBC

11.02B

ASTS

AST SpaceMobile Inc

33.23B

RKLB

Rocket Lab Corp

37.62B

give me top 10

Intellectia · 50 candidates

Market Cap: >= 5.00BRegion: USAnalyst Consensus: Strong BuyAnalyst Action: UpgradeList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

WULF

Terawulf Inc

6.22B

KGC

Kinross Gold Corp

36.68B

AMD

Advanced Micro Devices Inc

315.31B

AVGO

Broadcom Inc

1.53T

APP

Applovin Corp

154.70B

MDB

MongoDB Inc

20.94B

strong buy best stock to trade next week ?

Intellectia · 84 candidates

Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNASOne Week Rise Prob: >= 70Monthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

ECL

Ecolab Inc

86.95B

ASND

Ascendis Pharma A/S

14.47B

WBS

Webster Financial Corp

11.63B

Nu Holdings Ltd

72.74B

MP Materials Corp

10.46B

TSM

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

stock to increase price today and tomorrow

Intellectia · 116 candidates

Price Change Pct: >= $0.01Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 65One Day Predict Return: >= 1.0%

Ticker

Name

Market Cap$

PED

PEDEVCO Corp

59.31M

FBP

First BanCorp

3.52B

JRSH

Jerash Holdings (US) Inc

41.91M

RHP

Ryman Hospitality Properties Inc

6.43B

Kestrel Group Ltd

92.75M

SIFY

Sify Technologies Ltd

1.08B

Show me stocks with strong buy sentiment

Intellectia · 45 candidates

Market Cap: >= 10.00BAnalyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 10.0%List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

4.58T

MSFT

Microsoft Corp

3.07T

AVGO

Broadcom Inc

1.61T

AMD

Advanced Micro Devices Inc

348.21B

SAP

SAP SE

247.14B

APP

Applovin Corp

159.83B

Day projection December 5 2025

Intellectia · 65 candidates

Market Cap: >= 10.00BAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

4.45T

MSFT

Microsoft Corp

3.30T

AVGO

Broadcom Inc

1.56T

Whales Holding ALNY

Bluebox Asset Management Uk Ltd.

Deerfield Management Company, L.P.

Bellevue Asset Management AG

Jacobs Levy Equity Management Inc

Voleon Capital Management LP

Lombard Odier Asset Management (Switzerland) SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Alnylam Pharmaceuticals Inc (ALNY) stock price today?

The current price of ALNY is 319.35 USD — it has increased 2.02

What is Alnylam Pharmaceuticals Inc (ALNY)'s business?

What is the price predicton of ALNY Stock?

Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is479.53 USD with a low forecast of 351.00 USD and a high forecast of 580.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.